The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi’s Pemphigus Trial Disappointment, Humanigen’s COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 8)
This Smart Monitor Company Has Outperformed Apple, Google And Amazon Over The Last 5 Years
A smart monitor company that received FDA approval in 2015 has seen a five-year stock performance that has outperformed the returns of Apple Inc (NASDAQ: AAPL), Alphabet Inc (NASDAQ: GOOG)(NASDAQ:
Shares Of Abbott Laboratories (ABT) Rise Above Previous 52-Week High
Abbott Laboratories (NYSE: ABT) traded today at a new 52-week high of $129.40.
Shares Of Abbott Laboratories (ABT) Rise Above Previous 52-Week High
Abbott Laboratories (NYSE: ABT) traded today at a new 52-week high of $129.40.
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 2)
BTIG Maintains Buy on Abbott Laboratories, Raises Price Target to $136
BTIG analyst Marie Thibault maintains Abbott Laboratories (NYSE:ABT) with a Buy and raises the price target from $126 to $136.
Abbott Says Amulet Superior To Boston Scientific’s Watchman In Stroke Study
Abbott Laboratories (NYSE:ABT) has announced late-breaking data from the Amulet LAA Occluder IDE trial. The head-to-head study compared Abbott’s Amplatzer Amulet…
Abbott Laboratories Says Late-Breaking Data Shows Co’s Amplatzer Amulet Occluder Offers ‘Superior Left Atrial Appendage Closure’ Compared To Watchman Device For People With Atrial Fibrillation At Risk Of Stroke
Abbott (NYSE:ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company's Amplatzer™ Amulet Left Atrial Appendage (LAA)
Abbott Highlights Results Of GUIDE-HF Trial Assessing CardioMEMS Device
Abbott (NYSE:ABT) today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits of the CardioMEMS™ HF System in people living